levonorgestrel has been researched along with oxyntomodulin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flint, A; Hartvig, H; Jensen, CB; Jensen, L; Kapitza, C; Nosek, L | 1 |
| Albayaty, M; Anderson, TW; Breitschaft, A; Bækdal, TA; Christiansen, E; Houshmand-Øregaard, A; Jordy, AB; Manigandan, E | 1 |
1 trial(s) available for levonorgestrel and oxyntomodulin
| Article | Year |
|---|---|
Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
Topics: Ethinyl Estradiol; Female; Furosemide; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Levonorgestrel; Male; Postmenopause; Rosuvastatin Calcium | 2021 |
1 other study(ies) available for levonorgestrel and oxyntomodulin
| Article | Year |
|---|---|
Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
Topics: Aged; Area Under Curve; Blood Glucose; Contraceptives, Oral, Combined; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Levonorgestrel; Metabolic Clearance Rate; Middle Aged; Postmenopause | 2015 |